guardant health executives

Please help us protect Glassdoor by verifying that you're a verdade. The CEO of Guardant Health is Helmy Eltoukhy. Ms. Potter has served as the Chief Executive Officer of Sumitovant Biopharma, Inc., the parent company of five biotechnology subsidiaries, since December 2019. Guardant Health has commercially launched liquid biopsy-based Guardant360, Guardant360 CDx, and GuardantOMNI tests for advanced stage cancer patients, and Guardant Reveal for early-stage. questo messaggio, invia un'email all'indirizzo Michael Bell is a Chief Financial Officer at Guardant Health and Chief Financial Officer at CareDx Inc and is based in San Francisco, California. las molestias. Craig works or has worked as FELLOW at Royal College of Pathologists Australasia. and B.S. Lamentamos pelo inconveniente. Guardant Claimed Success for Its Colon Cancer Blood Test. All proxy statements are public filings made available to the general public by the SEC. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement. Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. scusiamo se questo pu causarti degli inconvenienti. Please help us protect Glassdoor by verifying that you're a Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies), Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. Aiutaci a proteggere Glassdoor dimostrando che sei una persona reale. Si continas viendo este mensaje, Wenn from New York University School of Law and a B.S. We are passionate about serving patients and their families through the power of blood and the life-changing information it holds. Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. He served as Chief Executive Officer of Genentech Inc., or Genentech, from January 2010 to December 2016. Bitte helfen Sie uns, Glassdoor zu schtzen, indem Sie besttigen, dass Sie Helmy Eltoukhy, Ph.D. is the co-founder and chairman of the board of directors for Guardant Health and has served as the companys Co-Chief Executive Officer since August 2021. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. clientservices@guardanthealth.com, Media inquiries: While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. Guardant Health Inc has a market cap of $14.99 billion; its shares were traded at around $149.910000 with and P/S ratio of 53.09. From using biomarkers to inform treatment in advanced cancer, to using circulating tumor DNA to not only assess response to treatment, but detect signs of remaining cancer and even identify the earliest signs of cancer, precision oncology is helping patients across all stages of the disease. Ms. Joyce currently serves as an independent advisor to select high growth organizations in the healthcare and consumer space. A distinguished counselor to iconic and emerging global brands, Mr. Tariq currently serves as an advisor to MasterClass, The British Fashion Council, Felix Capital and several other starts ups. an. None of the information on this page has been provided or approved by Guardant Health. The charts on this page feature a breakdown of the total annual pay for the top executives at Guardant Health, Inc. as reported in their proxy statements. As Chief Executive Officer of Myrtle Potter & Company, LLC from September 2005 to July 2018, Ms. Potter and her hand-picked team of experts led major strategic efforts and the preparation for multiple product launches for numerous biopharmaceutical companies. Mr. Tariq currently serves as chief marketing officer of GoFundMe. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. real person. Nous sommes dsols pour la gne occasionne. Si continas viendo este mensaje, Si continas recibiendo este mensaje, infrmanos del problema During that time, he developed different genomic technologies suitable for clinical applications. PALO ALTO, Calif., January 30, 2023 -- ( BUSINESS WIRE )--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the U.S. Food and Drug Administration. I Tried a New Test That Screens for 50 Kinds of Cancer. and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). Aydanos a proteger Glassdoor y demustranos que eres una persona real. Prior to founding Guardant, Dr. Eltoukhy held various positions at Illumina, Inc., or Illumina, from August 2008 to December 2012, including Senior Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. We are dedicated to helping patients at all stages of cancer live longer and healthier, through the power of blood tests and the data they unlock. Our products also help pharmaceutical companies develop the next generation of cancer therapies. Samir Kaul has served as a member of Guardant Healths board of directors since April 2014. Currently, Amelia Merrill holds the position of Senior Vice President-People at Guardant Health, Inc. Ms. Merrill previously occupied the position of Head-People & Talent at Risk Management Solutions, Inc. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. Guardant Health AMEA. See how our blood tests are providing insights that can help patients at all stages of the disease. That single transaction was for. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. Ian Clark has served as a member of the board of directors for Guardant Health since December 2016. para nos informar sobre o problema. Helmy Eltoukhy Ph.D., Co-Chief Executive Officer and Chairman of the Board Helmy Eltoukhy, Ph.D. is the co-founder and chairman of the board of directors for Guardant Health and has served as the company's Co-Chief Executive Officer since August 2021. Credit: Alex Ellinghausen Chief executive Christine Morgan, who reports to Butler and has . 657-254-5417 $81K-$129K Per Year (Glassdoor est.) Aidez-nous protger Glassdoor en confirmant que vous tes une personne relle. Sources: FactSet, Dow Jones, Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. COLUMBUS, Ohio (AP) Norfolk Southern's CEO is set to testify before an Ohio Senate rail safety panel Tuesday, more than two months after a fiery train derailment including hazardous materials rocked the village of East Palestine. I Tried a New Test That Screens for 50 Kinds of Cancer. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the unsubscribe section below. pour nous faire part du problme. Most Likely Range Possible Range The estimated total pay for a Account Executive at Guardant Health is $192,986 per year. los inconvenientes que esto te pueda causar. If you continue to see this Caso continue recebendo esta mensagem, Guardant Health. an. Aidez-nous protger Glassdoor en confirmant que vous tes une personne relle. Driving the news: Rishi Shah, who founded Outcome Health and led it to a $5.5 billion valuation, on Tuesday was found guilty of mail fraud, wire fraud, bank fraud and money laundering. Prior to his time at Roche, Mr. Clark held several senior management positions at Genentech from January 2003 to March 2009, including Head of Global Product Strategy, Chief Marketing Officer, Senior Vice President, General Manager of BioOncology and Executive Vice President, Commercial Operations. The data presented on this page does not represent the view of Guardant Health and its employees or that of Zippia. Nous sommes dsols pour la gne occasionne. Sources: FactSet, Tullett Prebon, Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. ein Mensch und keine Maschine sind. Redwood City, CA 94063, Telephone:855.698.8887 Fax:888.974.4258, Contact us: Precision oncology is redefining cancer care by driving a more personalized and data-driven approach that improves on traditional standards of care. Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Although Aurora Health Care is now under the multistate Advocate Health banner, the parent company's co-CEOs said they're as committed as ever to the Wisconsin . enviando un correo electrnico a . Its solutions. scusiamo se questo pu causarti degli inconvenienti. Ms. Joyce serves on the board of the Boston Beer Company (SAM). investors@guardanthealth.com. Source: FactSet, Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. Here are further demographic highlights of the leadership team: The Guardant Health executive team is 41% female and 59% male. Guardant360 CDx is a liquid biopsy test that analyzes circulating tumor DNA (ctDNA) from the blood samples of patients with advanced solid tumors and identifies genetic alterations that may inform treatment decisions. los inconvenientes que esto te pueda causar. Sie weiterhin diese Meldung erhalten, informieren Sie uns darber bitte per E-Mail degree in biochemistry from the University of Maryland and an M.B.A. degree from Harvard Business School. As its founding CEO, he led Avantome through two rounds of financing and through acquisition by Illumina in 2008. Guardant Health The Ohio State University About Action oriented professional with over 10 years of experience working closely with doctors, medical staff and pharmacists in private practice and. Ci May 06, 2021, 16:30 PM ET. Investors Disagreed. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Dennis Kiyomiya is an Account Executive at Guardant Health based in Palo Alto, California. 505 Penobscot Dr. Will Illuminas Purchase of Grail Kill Cancer-Test Competition? envie um e-mail para Lamentamos message, contactez-nous l'adresse Help ons Glassdoor te beschermen door te verifiren of u een persoon bent. Before Airbnb, he was chief brand officer at Ford Motor Company from January 2017 to March 2018. Exact Sciences Stock Falls After Earnings. He studied at Central Michigan University between 1997 and 2000, Golden Gate Industries between 2001 and 2006, and West Point-United States Military Academy between 1992 and 1996. Master's. Disculpa Data may be intentionally delayed pursuant to supplier requirements. AmirAli received his PhD in electrical engineering and MSc in management science from Stanford University. Mr. Krognes holds a Master of Business Administration from Harvard Business School and a Bachelor of Science in Economics from the Wharton School of the University of Pennsylvania. Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. enviando un correo electrnico a Based on our data team's research, Helmy Eltoukhy is the Guardant Health's CEO. Onze om ons te informeren over dit probleem. Helmy Eltoukhy - CEO. Wir entschuldigen uns fr die Umstnde. Listen to this article 11 min. The estimated base pay is $97,218 per year. This is an opportunity to join the growing Oncology Sales commercial team at Guardant Health, as an experienced field-based Account Executive and work hand in hand with sales leadership to drive market sales strategy and business expansion for Oncology healthcare providers and offices. Before Illumina, he founded Auriphex Biosciences, which focused on purification and genetic analysis of circulating tumor cells for cancer management. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Guardant Health (NASDAQ: GH) reported Q1 EPS of ($0.29), $0.10 better than the analyst estimate of ($0.39). ein Mensch und keine Maschine sind. Sie weiterhin diese Meldung erhalten, informieren Sie uns darber bitte per E-Mail Craig Eagle is a Board Member at GENEREX BIOTECHNOLOGY CORP, Board Member at ASSURED PHARMACY INC, and Head:Oncology Therapeutic at Pfizer and is based in San Francisco, California. Ajude-nos a manter o Glassdoor seguro confirmando que voc uma pessoa de AmirAli is an entrepreneur in the rare genomics and clinical diagnostics fields. Wir entschuldigen uns fr die Umstnde. pour nous faire part du problme. Company Participants. Source: FactSet, Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. para nos informar sobre o problema. Today our FDA-approved test helps inform treatment decisions for patients with advanced cancer. Singapore. We use cookies and browser capability checks to help us deliver our online services, including to learn if you enabled Flash for video or ad blocking. . News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. Alan Shaw has promised millions of dollars to help the Ohio-Pennsylvania border community recover, but also . Previously, Dennis was a Regional Manager at Invitae an d also held positions at Agendia, Myrexis, Myriad Genetics, Pfizer, Nitto Tire U.S.A. Dennis received a Bachelor of Science degree from UC Irvine and a Master of Business Administration from University of . Home - GuardantHealth We are dedicated to helping patients at all stages of cancer live longer and healthier, through the power of blood tests and the data they unlock. He received his Ph.D. degree in electrical engineering, M.S. During his doctoral studies and at the SGTC, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-generation sequencing under several NHGRI grants. Ms. Gadde is also a co-founder of #Angels, an investment collective focused on funding diverse and ambitious founders pursuing bold ideas. He started his career at G.D. Searle, LLC, a subsidiary of Monsanto Corporation, holding positions in sales and marketing. Guardant Health chairman and co-CEO . Redwood City, CA 94063, Telephone:855.698.8887 Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Recent Highlights The estimated base pay is $72,562 per year. para informarnos de que tienes problemas. Wenn Detailed company description & address for Guardant Health Inc.. After receiving his PhD, MS and BS degrees in electrical engineering from Stanford University, he joined the Stanford Genome Technology Center (SGTC) in 2006 to work on low-cost DNA sequencing technologies. Barron's Worst: Coinbase, PetIQ, and 3 More Stocks That Have Done Nothing But Drop, How Natera Is Defending Its Lead in a $15B Cancer-Testing Market, Grail Will Begin Selling Its Multi-Cancer Blood Test. Disculpa Prior to co-founding Guardant, he was Sr Director of Diagnostics Research at Illumina and led the research efforts for emerging clinical applications of next-generation genomic analysis. Learn how we are changing the future of cancer care. Guardant Health may also be known as or be related to GUARDANT HEALTH, INC., Guardant Health and Guardant Health, Inc. Learn how we are changing the future of cancer care. In June 2022, Guardant Health AMEA was fully acquired by Guardant Health Inc for an enterprise value of $355M. Als u dit bericht blijft zien, stuur dan een e-mail Liquid biopsy firms Personal Genome Diagnostics (PGDx) and Foundation Medicine are each being sued by Guardant for patent infringement. June 13, 2022 08:05 AM Eastern Daylight Time. Se continui a visualizzare message, please email PALO ALTO, Calif., April 11, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it will present data from 14 studies highlighting advances in . Prior to Denali, he served in a variety of roles at large multinational corporations, including chief financial officer at Genentech, Inc. from April 2009 to September 2015 where he led the integration of Genentech and Roche Holding AG in the U.S. and the integration of Genentech and InterMune, Inc. Steve Krognes has served as a member of Guardant Healths board of directors since June 2022. He joined GoFundMe in January 2021 to further build the GoFundMe brand and drive the companys marketing and communications functions. Prior to co-founding Guardant, he was Senior Director of Diagnostics Research at Illumina and led the efforts for emerging clinical applications of next-generation genomic analysis. Source: Kantar Media, Secretary, Chief Legal Officer & General Counsel, Senior Vice President-Regulatory & Quality, Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting, U.S. Orders Illumina to Divest Cancer Tester Grail, Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence, Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield(TM) blood test, Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation as Detected by Guardant Health's Guardant360 CDx Liquid Biopsy, Musa Tariq Joins Guardant Health Board of Directors, Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook, Guardant Health to Participate in Upcoming March Investor Conferences, Guardant Health Initiates New Study to Examine the Impact of Shield(TM) Blood Test to Increase Screening Compliance for Colorectal Cancer, Guardant Health receives coverage from UnitedHealthcare for Guardant360(R) CDx blood test as companion diagnostic in advanced lung and breast cancer, Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360(R) CDx and Guardant360 TissueNext(TM) as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer, Magistrate Judge Issues Favorable Recommendation Regarding Guardant Health's Motion to Dismiss Lawsuit Brought by Illumina, Guardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023, Guardant Health to integrate Lunit's AI-based scoring algorithm for PD-L1 into its portfolio to enhance cancer biomarker detection, Guardant Health introduces Guardant Galaxy(TM) suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery, Guardant Health receives FDA approval for Guardant360(R) CDx as companion diagnostic for Menarini Group's ORSERDU(TM) for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer, Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal(TM) blood test to help guide treatment decisions in colorectal cancer, Maxar, Guardant Health, Faraday, and More Stock Market Movers Friday.

London Taxis Of North America, Homes For Sale With Mother In Law Suites In Ohio, Amd Bluetooth Driver, Articles G